Approval · Notice of Compliance 342 · 2002
ATACAND: Notice of Compliance 342
Issued October 8, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 342
- Date
- October 8, 2002
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New dosing regimen: starting dose of 16mg once daily when used as monotherapy, and a maximum daily dose of 32mg
- Therapeutic class
- Angiotensin II at1 receptor blocker
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ATACAND | Not yet assigned | — |
Medicinal ingredients
- CANDESARTAN CILEXETIL 8 MG per TAB
- CANDESARTAN CILEXETIL 16 MG per TAB